Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis

Table 1 Baseline characteristics of the studies included in the meta-analysis

Ref.	Year	Country	Cutoff(109/L)	Therapy	Adjusted HR	Recurrence type	Men	Women	Recurrence	Follow-up time (mo)	LoE
Saito et al[32]	2014	Japan	100	PH + RFA	No	Overall	38	13	39	39.9-46.6	4
Kaibori et al[19]	2013	Japan	150	PH	Yes	Overall	60	14	14	151.2	2a
Shiina et al[24]	2012	Japan	100	RFA	Yes	Distant	751	419	740	38.2	2b
Nishikawa et al[25]	2012	Japan	100	RFA	Yes	Distant	114	68	86	36.4	2b
Kao et al[26]	2012	TaiWan	100	RFA	Yes	Overall	162	96	163	28.5	2b
Miyatake et al[33]	2012	Japan	100	PH + PTA	Yes	Overall	260	135	277	42-46	2b
Ikeda et al[20]	2011	Japan	150	RFA	No	Overall	68	39	55	12	4
Amano et al[21]	2011	Japan	100	PH	No	Overall	127	24	107	49.2	4
Ishikawa et al[31]	2011	Japan	100	TACE	Yes	Distant	47	31	46	36.6	1b
Hagihara et al[34]	2011	Japan	100	PH + PTA	No	Overall	124	58	81	44.4	4
Nonaka et al[22]	2010	Japan	100	PH	No	Overall	42	22	32	12	4
Kang et al[23]	2009	Korea	100	PH	No	Overall	125	42	78	38	4
Fuke et al[28]	2008	Japan	100	RFA	Yes	Distant	80	37	90	29.1	2b
Nouso et al[27]	2008	Japan	100	RFA	No	Overall + distant	415	206	589	34.7	4
Jeong et al[35]	2007	Japan	100	PH + medical	Yes	Overall	65	19	50	32	2b
Tateishi et al[29]	2006	Japan	100	RFA	No	Overall	276	140	277	NR	4
Yamanaka et al[30]	2005	Japan	100	RFA	Yes	Distant	17	9	14	18	2b
Ikeda et al[36]	2000	Japan	100	PH + RFA	No	Overall	13	7	8	25	4

LoE: Level of evidence; NR: Not reported; PH: Partial hepatectomy.